Who are Daratumumab-hyaluronidase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Darzalex Faspro, Darzalex, SARCLISA, SCT800 and Daratumumab, Daratumumab and corticosteroid treatment, DARATUMUMAB (DARZALEX®).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daratumumab-hyaluronidase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Daratumumab-hyaluronidase — Competitive Intelligence Brief

Daratumumab-hyaluronidase (Daratumumab-hyaluronidase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody-drug conjugate. Area: Oncology.

phase 2 Monoclonal antibody-drug conjugate CD38 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Daratumumab-hyaluronidase (Daratumumab-hyaluronidase) — Eastern Cooperative Oncology Group. Daratumumab-hyaluronidase is a monoclonal antibody-drug conjugate that targets CD38 on cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Daratumumab-hyaluronidase TARGET	Daratumumab-hyaluronidase	Eastern Cooperative Oncology Group	phase 2	Monoclonal antibody-drug conjugate	CD38
Darzalex Faspro	daratumumab-and-hyaluronidase-fihj	Pfizer	marketed	CD38-directed Cytolytic Antibody [EPC]	CD38	2020-01-01
Darzalex	daratumumab	Johnson & Johnson	marketed	Monoclonal antibody	CD38	2015-01-01
SARCLISA	ISATUXIMAB-IRFC	SANOFI AVENTIS US	marketed	CD38-directed Cytolytic Antibody [EPC]	Lymphocyte differentiation antigen CD38
SCT800 and Daratumumab	SCT800 and Daratumumab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab)	CD19 and CD3 (SCT800); CD38 (Daratumumab)
Daratumumab and corticosteroid treatment	Daratumumab and corticosteroid treatment	Institute of Hematology & Blood Diseases Hospital, China	marketed	Monoclonal antibody (CD38-targeting) combined with corticosteroid	CD38
DARATUMUMAB (DARZALEX®)	DARATUMUMAB (DARZALEX®)	Hospices Civils de Lyon	marketed	CD38-targeting monoclonal antibody	CD38

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody-drug conjugate class)

GlaxoSmithKline · 2 drugs in this class
RemeGen Co., Ltd. · 2 drugs in this class
Copharos · 1 drug in this class
Eastern Cooperative Oncology Group · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mirati Therapeutics Inc. · 1 drug in this class
NYU Langone Health · 1 drug in this class
The Lymphoma Academic Research Organisation · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
Yan Zhang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daratumumab-hyaluronidase — Competitive Intelligence Brief. https://druglandscape.com/ci/daratumumab-hyaluronidase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab